Search
Olopatadine
go.drugbank.com/drugs/DB00768Approved[A1172] In comparison to other anti-allergenic ophthalmic medications, olopatadine displays a good comfort and tolerability profile since it does not cause perturbation of cell membranes. … Olopatadine is a selective histamine H1 antagonist and mast cell stabilizer that works by attenuating inflammatory and allergic reactions.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: OLOPATADINE HYDROCHLORIDE TABLETS 5 MG MEIJI, PALLADA-NS %6.65 MG/ML NAZAL SPREY, 30 MLPancuronium
go.drugbank.com/drugs/DB01337ApprovedAs a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.
Products: BROMURO DE PANCURONIO 4 MG/2 ML, BROMURO DE PANCURONIO 2 MG/MLNicotinamide
go.drugbank.com/drugs/DB02701ApprovedInvestigationalMost animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.
Mixtures: Multivitamin with 1.0 mg Fluoride, MOL-IRON PANEM 500 MGCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsPhenothrin
go.drugbank.com/drugs/DB13717InvestigationalProducts: ANTI-BIT 408 MG/100 ML ŞAMPUAN, 150 ML, ANTI-BIT 408 MG/100 ML ŞAMPUAN, 100 MLDexlansoprazole
go.drugbank.com/drugs/DB05351ApprovedCompared to the older generation of PPIs (which includes [DB00213], [DB00338], and [DB00448]),[A178084] dexlansoprazole has a unique pharmacokinetic profile due to its delayed-release and dual-delivery … release system: This aims to address some limitations of the older-generation PPIs, such as short plasma half-life and the need for meal-associated dosing.
Mixtures: DUEDOM 60/10 MG KAPSÜL, 30 ADET, DUEDOM 30/10 MG KAPSÜL, 30 ADETCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSelumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigational[A193533] Following its initial FDA approval on April 10, 2020,[L49991] and Health Canada approval on August 23, 2022,[L49986] the regulatory landscape has evolved. … Most recently, on November 20, 2025, the FDA expanded this indication to include adults [L53881]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: Koselugo Hard Capsules 10 mg, Koselugo Hard Capsules 25 mgIcatibant
go.drugbank.com/drugs/DB06196ApprovedInvestigationalIcatibant is a synthetic decapeptide with 5 nonproteinogenic amino acid antagonist targeting the B<sub>2</sub> receptors with a similar affinity to bradykinin. … relief was observed to be 8 hours compared to 36 hours for the placebo treatment.
Products: Icatibant Reddy 30 mg/3 ml Injektionslösung in einer Fertigspritze, İKTU 30 MG/3 ML ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETCeftazidime
go.drugbank.com/drugs/DB00438ApprovedInvestigational[L32935] Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor [avibactam] to treat a variety of
Mixtures: ZAVİCEFTA 2 G/0.5 G İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 10 ADET, CEFAZIME FOR INJECTION 1 g/vialProducts: Kefazim 500 mg Trockenstechampulle, SEFAVİS 500 MG IM/IV ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 FLAKON VE 1 AMPULManganese gluconate
go.drugbank.com/drugs/DB11141ApprovedIt is typically obtained by reacting manganese carbonate with gluconic acid in aqueous medium and then crystallizing the product to form a slightly pink powder.
Mixtures: Vital Be-100, Cal-mag Plus K, Mn and Zn CapletsProducts: Manganese (gluconate) 10 Mg TabletsBumetanide
go.drugbank.com/drugs/DB00887ApprovedInvestigationalBumetanide is a sulfamyl diuretic.
Mixtures: BURINEX TABLET 1 mg, BURINEX TABLET 1 mgSynonyms: 3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid, 3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid